Last updated on November 2019

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS) Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (AML)


Find a site near you

Start Over

Kindai University Hospital

Osakasayama, Japan
1.93miles
  Connect »